Generation Bio Inc. (GBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
GBIO Stock Price Chart Interactive Chart >
GBIO Price/Volume Stats
| Current price | $5.33 | 52-week high | $19.55 |
| Prev. close | $5.12 | 52-week low | $3.96 |
| Day low | $5.01 | Volume | 208,067 |
| Day high | $5.35 | Avg. volume | 355,919 |
| 50-day MA | $5.48 | Dividend yield | N/A |
| 200-day MA | $6.05 | Market Cap | 316.72M |
Generation Bio Inc. (GBIO) Company Bio
Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Latest GBIO News From Around the Web
Below are the latest news stories about GENERATION BIO CO that investors may wish to consider to help them evaluate GBIO as an investment opportunity.
Wall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a BetThe consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Generation Bio Reports Business Highlights and Third Quarter 2022 Financial ResultsCash balance of $301.2M expected to fund operations into 2025CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2022 financial results. “Generation Bio’s mission is to unlock the full promise of genetic medicine by developing novel durable, redosable and titratable DNA therapeutics,” said Geoff McDonough, M.D., |
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine SummitCAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on Thursday, September 29th at 10:30 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. |
Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy OfficerCAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer. Dr. Samayoa has led strategy, corporate and portfolio development at Generation Bio since he joined the company in 2017, most recently serving as senior vice president. “Phillip has been instrumental in building a holistic strate |
GBIO Price Returns
| 1-mo | 4.10% |
| 3-mo | -0.19% |
| 6-mo | -6.16% |
| 1-year | -68.96% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -24.72% |
| 2021 | -75.03% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...